New shot could help kids with relapsed leukemia

NCT ID NCT07134088

Ongoing Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jan 09, 2026 · Last updated May 24, 2026 · Updated 18 times

Summary

This study tests a new way to give the drug blinatumomab (under the skin, like a shot) to children under 12 with a type of leukemia that has come back or not responded to treatment. The goal is to see if this method is safe and can help get rid of the cancer. About 104 children will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Childrens Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Kanagawa Childrens Medical Center

Yokohami-shi, Kanagawa, 232-8555, Japan
Lucile Packard Childrens Hospital Stanford

Palo Alto, California, 94304, United States
Seattle Childrens Hospital

Seattle, Washington, 98105, United States
St Jude Childrens Research Hospital

Memphis, Tennessee, 38105, United States

Conditions

Explore the condition pages connected to this study.

MINIMAL RESIDUAL DISEASE + B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA MINIMAL RESIDUAL DISEASE + B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSED/REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA